Cogent Biosciences, Inc. COGT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$97.35M+5.0% | -$102.49M-26.6% | -$80.93M-10.1% | -$73.53M-2.1% | -$71.99M-6.0% | ||
| $626K-0.3% | $628K-2.0% | $641K-2.1% | $655K+2.3% | $640K+2.4% | ||
| $16.91M+7.3% | $15.75M+48.5% | $10.6M+9.1% | $9.72M-2.9% | $10.01M+0.3% | ||
| $278K+16.8% | $238K-20.7% | $300K+376% | $63K— | $0— | ||
| -$135K— | —— | —— | —— | -$0— | ||
| $4.24M+165% | -$6.53M-995% | -$596K-124% | $2.47M+15.4% | $2.14M— | ||
| -$10.2M-212% | $9.1M+99.3% | $4.57M-19.6% | $5.68M+166% | -$8.66M-253% | ||
| $1.84M-43.3% | $3.24M+501% | -$806K-1,179% | -$63K+97.1% | -$2.17M-164% | ||
| $29K+123% | $13K+18.2% | $11K+175% | $4K-20.0% | $5K— | ||
| $529K+3.1% | $513K+1.4% | $506K+0.8% | $502K+0.8% | $498K+3.1% | ||
| —— | -$1.8M0.0% | -$1.8M0.0% | -$1.8M0.0% | -$1.8M— | ||
| -$86.88M-9.8% | -$79.11M-23.1% | -$64.29M-17.9% | -$54.54M+18.0% | -$66.51M-9.8% | ||
| $449K-44.6% | $811K+1,148% | $65K-50.4% | $131K-76.1% | $547K+629% | ||
| -$36.46M+88.7% | -$322.77M-108% | -$155.05M-1,840% | $8.91M-87.2% | $69.38M+12.5% | ||
| —— | $13.66M0.0% | $13.66M0.0% | $13.66M0.0% | $13.66M— | ||
| $5.76M-44.4% | $10.36M+892% | $1.04M+20,780% | $5K-96.3% | $136K— | ||
| —— | $12.22M0.0% | $12.22M0.0% | $12.22M0.0% | $12.22M— | ||
| $52.54M-91.1% | $588.67M+171% | $217.37M+360% | $47.23M+89.1% | $24.97M+95,938% | ||
| -$70.8M-138% | $186.8M— | $0-100% | $1.6M-94.3% | $27.84M+2,386% | ||
| $1.18M+11.7% | $1.06M+532% | $167K— | —— | $955K-63.3% | ||
| $278K+16.8% | $238K-20.7% | $300K+376% | $63K— | $0— | ||
| —— | $641K0.0% | $641K0.0% | $641K0.0% | $641K+4.7% | ||
| -$10.2M-212% | $9.1M+99.3% | $4.57M-19.6% | $5.68M+166% | -$8.66M-253% | ||
| -$422K-3.7% | -$407K-1.8% | -$400K-4.7% | -$382K-1.6% | -$376K-3.9% | ||
| -$1.36M-14.7% | -$1.19M-217% | -$374K— | $0— | -$0+100% | ||
| $1.84M-43.3% | $3.24M+501% | -$806K-1,179% | -$63K+97.1% | -$2.17M-164% | ||
| $529K+3.1% | $513K+1.4% | $506K+0.8% | $502K+0.8% | $498K+3.1% | ||
| —— | $55.78M0.0% | $55.78M0.0% | $55.78M0.0% | $55.78M— | ||
| $1.06M— | —— | $766K— | —— | $584K— | ||
| $45.71M-66.2% | $135.07M— | —— | —— | $24.25M— | ||
| —— | $13.66M0.0% | $13.66M0.0% | $13.66M0.0% | $13.66M— | ||
| —— | —— | —— | —— | —— | ||
| $152K— | —— | —— | —— | $79K— | ||
| -$87.33M-9.3% | -$79.92M-24.2% | -$64.35M-17.7% | -$54.67M+18.5% | -$67.06M-10.6% | ||
| -$87.33M-9.3% | -$79.92M-24.2% | -$64.35M-17.7% | -$54.67M+18.5% | -$67.06M-10.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Cogent Biosciences, Inc. generate?
- Cogent Biosciences, Inc. (COGT) generated -$284.8M in operating cash flow over the trailing twelve months.
- What is Cogent Biosciences, Inc.'s free cash flow?
- After $1.5M of capital expenditures, Cogent Biosciences, Inc.'s free cash flow was -$286.3M over the trailing twelve months, down 28.5% year over year.
- Where does Cogent Biosciences, Inc.'s cash flow data come from?
- Every line is extracted from Cogent Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
